ECONOMIC BURDEN OF PROGRESSIVE SUPRANUCLEAR PALSY: A TARGETED LITERATURE REVIEW
Author(s)
Taruni Donkana, Pharm D, Vijay Sharma, M. Pharm in Clinical Research, Prakhar Lambhate, M. Pharm (Pharmacy Practice).
Lumanity, Gurugram, India.
Lumanity, Gurugram, India.
OBJECTIVES: Progressive supranuclear palsy (PSP) is a rare, progressive neurodegenerative disorder associated with increasing disability and long-term care needs. This targeted literature review (TLR) aimed to identify and summarize published economic evidence on PSP, including healthcare costs, healthcare resource utilization (HCRU), and cost-effectiveness outcomes, to identify evidence gaps for future research.
METHODS: A TLR was conducted in Embase® from database inception to June 2026 using predefined eligibility criteria. Studies reporting healthcare costs, resource utilization, caregiver burden, productivity losses, or cost-effectiveness outcomes in patients with PSP were included.
RESULTS: Eight studies published between 2011 and 2025 evaluated the economic burden of PSP. The included studies comprised cost-of-illness analyses, observational studies, retrospective database studies, HCRU studies, and economic evaluations conducted across Europe, North America, and Israel. Cost-of-illness studies reported substantial healthcare and societal costs, with 6-month per-patient costs ranging from €24,491 to €30,643 in Europe, while informal caregiving accounted for 68.0-76.0% of total costs. An Israeli claims-based study showed that annual direct medical costs increased from US$8,910 before diagnosis to US$36,693 by Year 10 after diagnosis. HCRU was high, with frequent use of medications (100.0%), imaging (99.0%), assistive devices (90.0%), supportive care services (86.0%), and procedures (85.0%). Patients often required multidisciplinary care, home adaptations, and informal caregiving, while caregivers experienced notable productivity losses, including absenteeism (5.2%), presenteeism (28.0%), and activity impairment (43.1%). Evidence on cost-effectiveness was scarce; only one study identified estimated net savings of approximately £286,000 over 3 years with preventive zoledronate therapy through reduced fracture-related events and healthcare costs.
CONCLUSIONS: Available evidence suggests PSP is associated with substantial healthcare costs and caregiver burden, while evidence on cost-effectiveness remains limited.
METHODS: A TLR was conducted in Embase® from database inception to June 2026 using predefined eligibility criteria. Studies reporting healthcare costs, resource utilization, caregiver burden, productivity losses, or cost-effectiveness outcomes in patients with PSP were included.
RESULTS: Eight studies published between 2011 and 2025 evaluated the economic burden of PSP. The included studies comprised cost-of-illness analyses, observational studies, retrospective database studies, HCRU studies, and economic evaluations conducted across Europe, North America, and Israel. Cost-of-illness studies reported substantial healthcare and societal costs, with 6-month per-patient costs ranging from €24,491 to €30,643 in Europe, while informal caregiving accounted for 68.0-76.0% of total costs. An Israeli claims-based study showed that annual direct medical costs increased from US$8,910 before diagnosis to US$36,693 by Year 10 after diagnosis. HCRU was high, with frequent use of medications (100.0%), imaging (99.0%), assistive devices (90.0%), supportive care services (86.0%), and procedures (85.0%). Patients often required multidisciplinary care, home adaptations, and informal caregiving, while caregivers experienced notable productivity losses, including absenteeism (5.2%), presenteeism (28.0%), and activity impairment (43.1%). Evidence on cost-effectiveness was scarce; only one study identified estimated net savings of approximately £286,000 over 3 years with preventive zoledronate therapy through reduced fracture-related events and healthcare costs.
CONCLUSIONS: Available evidence suggests PSP is associated with substantial healthcare costs and caregiver burden, while evidence on cost-effectiveness remains limited.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE723
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Trial-Based Economic Evaluation, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Rare & Orphan Diseases